Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-Year outcome

British Journal of Ophthalmology

Volumn 97, Issue 11, 2013, Pages 1447-1450

  Ruiz Moreno, Jose M ^a,b   Arias, Luis ^c   Montero, JavierA ^d,e   Carneiro, Angela ^f   Silva, Rufino ^g  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b Alicante   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^e Oftalvist   (Spain)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

^g CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; DRUSEN; EYE EXAMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYOPIA; PHOTODYNAMIC THERAPY; PORTUGAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPAIN; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY; YOUNG ADULT;

ANGIOGENESIS; DRUGS; MACULA; RETINA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84888643134     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302973     Document Type: Article

References (32)

1. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001;108:841-52.
2. Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010;30:407-12.
3. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100e1.
4. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005;89:1368-70. (Pubitemid 41638883)
5. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, et al. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-51.
6. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-5. (Pubitemid 46202863)
7. Hayashi K, Shimada N, Moriyama M, et al. Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina 2012;32:687-95.
8. Gharbiya M, Cruciani F, Parisi F, et al. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2012;96:1068-72.
9. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
10. Lai TY, Luk FO, Lee GK, et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 2012;26:1004-11.
11. Hefner L, Riese J, Gerding H. Three Years Follow-up Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathologic Myopia. Klin Monbl Augenheilkd 2013;230:401-4.
12. Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol 2012;47:28-33.
13. Ruiz-Moreno JM, Montero JA, Arias L, et al. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization. Acta Ophthalmol 2012;90:e82-3.
14. Baba T, Kubota-Taniai M, Kitahashi M, et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010;94:864-70.
15. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141:456-62. (Pubitemid 43265948)
16. Sawada O, Kawamura H, Kakinoki M, et al. Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization. Acta Ophthalmol 2011;89:459-62.
17. Shin YJ, Nam WH, Park SE, et al. Aqueous humor concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in high myopic patients. Mol Vis 2012;18:2265-70.
18. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007;91:157-60. (Pubitemid 46202862)
19. Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-4.
20. Gharbiya M, Allievi F, Mazzeo L, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84-93e1.
21. Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-6.
22. Ruiz-Moreno JM, Montero JA, Arias L, et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010;30:1609-15.
23. Hefner L, Riese J, Gerding H. [Results of ranibizumab treatment for choroidal neovascularization secondary to pathological myopia]. Klin Monbl Augenheilkd 2011;228:284-7.
24. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009;148:396-408.
25. Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010;149:140-6.
26. Ruiz-Moreno JM, Lopez-Galvez MI, Donate J, et al. Myopic choroidal neovascularization. Ophthalmology 2011;118:2521-3.
27. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010;30:418-24.
28. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65e5.
29. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 2010;248:937-41.
30. Chen CH, Wu PC, Chen YJ, et al. Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up. J Ocul Pharmacol Ther 2011;27:395-400.
31. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-9.
32. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab. Br J Ophthalmol 2009;93:1693-4.